Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study
Authors:
- Marousa KouvelaMarousa Kouvela
- Maria Effrosyni LivanouMLMaria Effrosyni Livanou
- Dimitra T. StefanouDSDimitra T. Stefanou
- Ioannis A. VathiotisIVIoannis A. Vathiotis
- Fotini SarropoulouFSFotini Sarropoulou
- Maria GrammoustianouMGMaria Grammoustianou
- Evangelos DimakakosEDEvangelos Dimakakos
- Nikolaos SyrigosNSNikolaos Syrigos
Open Access
Abstract
Background: The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. Methods: This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. Results: In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (p = 0.26 and p = 0.32, respectively). Conclusion: Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.Keywords
This publication has 36 references indexed in Scilit:
- Venous and Arterial Thromboembolism in Patients With CancerJACC: Cardiooncology, 2021
- Increased incidence of venous thromboembolism with cancer immunotherapyMed, 2021
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapyCochrane Database of Systematic Reviews, 2020
- Mechanism and management of cancer-associated thrombosisJournal of Cardiology, 2018
- Physicians’ decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in FranceSupportive Care in Cancer, 2018
- Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancerLung Cancer, 2012
- Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerEuropean Journal of Cancer, 2012
- Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database studyJournal of Thrombosis and Thrombolysis, 2012
- Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer centerCancer, 2011
- PREVENTION OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN INJURED PATIENTSThe Lancet, 1959